Nuclein

Nuclein, LLC is a biotechnology company based in Austin, Texas, founded in 2017. The company focuses on providing simple, affordable, rapid, and accurate diagnostic testing solutions. Nuclein specializes in advanced molecular diagnostic technologies, particularly point-of-care testing. The flagship product, the DASH® Rapid PCR System, is a handheld platform that delivers lab-quality PCR test results in just 15 minutes with minimal hands-on time. This system is designed for ease of use and affordability, enabling rapid testing outside traditional laboratory settings. It supports multiplex testing across various sample types and features Wi-Fi and cloud connectivity for data management. The primary marketed test on this system is the FDA-cleared DASH® SARS-CoV-2 & Flu A/B Test, which allows for quick and accurate detection of COVID-19 and influenza viruses. Nuclein has raised approximately $50 million in funding and merged with Minute Molecular Diagnostics in 2023. The company is led by a team of experienced professionals in nucleic acid assay development and diagnostic system integration, aiming to make high-quality testing widely accessible in diverse healthcare environments.

• Employees 66
• Founded 2017
• Total Funding $65913804